In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Immune Design (NASDAQ: IMDZ). The company’s shares opened today at $3.50, close to its 52-week low of $2.80.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 14.2% and a 48.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
The the analyst consensus on Immune Design is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.25 and a one-year low of $2.80. Currently, Immune Design has an average volume of 234.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.
